S181: THE PHASE III, RANDOMIZED COMMODORE 2 TRIAL: RESULTS FROM A MULTICENTER STUDY OF CROVALIMAB VS ECULIZUMAB IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) PATIENTS NAIVE TO COMPLEMENT INHIBITORS

• Alexander Röth,
• Guangsheng He,
• Andres Brodsky,
• Chatree Chatree Chai-Adisaksopha,
• Teresita Dumagay,
• Roberta Demichelis,
• Martin Höglund,
• Richard Kelly,
• Je-Hwan Lee,
• Jun-Ichi Nishimura,
• Naoshi Obara,
• Antonio Maria Risitano,
• Anna Gaya,
• Anita Appius,
• Brittany Gentile,
• Raluca Negricea,
• Zilu Zhang,
• Simon Buatois,
• Bing Han

Affiliations

Alexander Röth

1 University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University of Duisburg-Essen, Department of Hematology and Stem Cell, Essen, Germany

Guangsheng He

2 The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People’s Hospital in Nanjing, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalize, Nanjing, China

Andres Brodsky

3 Hospital de Clínicas “José de San Martín” Hematology Division, Buenos Aires, Argentina

Chatree Chatree Chai-Adisaksopha

4 Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand

Teresita Dumagay

5 University of the Philippines - Philippine General Hospital Oblation Statue, Division of Hematology, Department of Medicine, Manila, Philippines

Roberta Demichelis

6 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Department of Hematology, Mexico City, Mexico

Martin Höglund

7 Uppsala University, Department of Medical Sciences, Uppsala, Sweden

Richard Kelly

8 Leeds Institute of Medical Research at St James’s, University of Leeds, Division of Haematology and Immunology, Leeds, United Kingdom

Je-Hwan Lee

9 Asan Medical Center, University of Ulsan, College of Medicine, Department of Internal Medicine, Seoul, Korea, Rep. of South

Jun-Ichi Nishimura

10 Osaka University, Department of Hematology and Oncology, Osaka, Japan

Naoshi Obara

11 University of Tsukuba Hospital, Department of Hematology, Ibaraki, Japan

Antonio Maria Risitano

12 Hematology and BMT Unit, AORN San Giuseppe Moscati, Avellino, Italy

Anna Gaya

13 Hospital Clínic Barcelona, Hematology Department, Barcelona, Spain

Anita Appius

14 F. Hoffmann-La Roche, Ltd, Basel, Switzerland

Brittany Gentile

15 Genentech, Inc., South San Francisco, CA, United States

Raluca Negricea

16 Roche Products Ltd, Welwyn Garden City, United Kingdom

Zilu Zhang

17 Roche Product Development, Shanghai, China

Simon Buatois

14 F. Hoffmann-La Roche, Ltd, Basel, Switzerland

Bing Han

18 Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Department of Hematology, Peking, China